A significant decrease in steatosis using non-invasive measurements during monitoring for life style changes in patients with MASLD: interim 6 m results of a monocentric study

Abstract

[−50%]) and P3NP (−6.5 ng/ml [−40%]). Significant reductions were also observed in mean PRO-C3 (−6.1 ng/ml [−30%], p = 0.0002) and ELF score (−0.63 units, p = 0.008). A similar, but more attenuated, effect was observed in the 300 mg ICO treatment arm for all biomarkers (range −19 to −28% versus baseline), whereas the placebo arm showed no significant change in any variable (range −7 to +3% versus baseline). In alignment with the observed decrease in HbA1c, ICO treatment reduced mean FPG by 21% (p = 0.01) and 20% (p = 0.007) versus baseline for 300 mg and 600 mg respectively (placebo unchanged). Irrespective of T2D status, 82% (9/11) of fibrosis in the 600 mg treatment arm had a combined decrease in ALT of >17 U/L and ELF score >0.5 units versus 13% in non-responders. Conclusion: Once-daily, oral therapy with 600 mg ICO induces pronounced reductions in multiple elevated markers of liver injury and fibrosis in T2D MASH patients. Furthermore, a simultaneous decrease in ALT and ELF score may help identify histological responders to ICO therapy. SAT-196 A significant decrease in steatosis using non-invasive measurements during monitoring for life style changes in patients with MASLD: interim 6 m results of a monocentric study Background and aims: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is an important cause of chronic liver disease. Currently, the cornerstone of therapy is lifestyle modification (diet and exercise). Using paired liver biopsy studies, a weight reduction of more than 5% of body weight (BW) might be sufficient to reduce steatosis (at least one stage). This study investigates the outcome of a reduction of more than 5% of body weight (BW) on steatosis in patients with MASLD using non-invasive methods. Method: In this ongoing, monocentric (Ziekenhuis Oost Limburg, Genk, Belgium), prospective study patients with MASLD (Controlled Attenuation Parameter CAP TM ≥215 dB/m) are consecutively included since October 2022 to receive lifestyle intervention during 1 year. After 6 months (M6) and 1 year they are re-evaluated (clinical and biochemical evaluation, as well as liver stiffness measurement (LSM) by transient elastography (FibroScan ®) and CAP TM). Results: From October 2022 until December 2023, 297 patients were included. Their mean age was 52 ± 12 years, 47 % were female, 9 % had type 2 diabetes, 40 % metabolic syndrome, 53 % were living with obesity, 20 % were known with arterial hypertension. As of the 31st of December 2023, 111 patients presented at the M6 control visit: 41 (37